MedPath

Evaluation of the Immuno-Stimulatory Potential (Shareera Bala) of an Ayurveda Management Protocol in Cohort of Quarantined Delhi Police under Covid-19 Care Centers- An Exploratory Clinical Study

Phase 2
Registration Number
CTRI/2020/05/025178
Lead Sponsor
All India Institute of Ayurveda
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Available police personnel of either sex aged 19-60 years

2.Delhi Police personnel quarantined for COVID-19 infection.

3.Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals.

4.Individuals agree to give consent for participation

Exclusion Criteria

1.Individuals with uncontrolled co morbid conditions which may affect the Bala of the Individual.

2.Already suffering with severe respiratory allergies and other conditions which may create bias in the outcome results

3.Individuals found positive for COVID 19 during the course of medication. Defined as: temperature > 38 Celsius; cough; shortness of breath; sore throat; or, if available (not required), positive confirmatory testing for COVID-19

4.Previously diagnosed with COVID-19

5.Subjects on other prophylactic medications.

6.Concurrent condition that in the investigatorâ??s opinion would jeopardize compliance with the protocol.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Improvement in Bala of an individual <br/ ><br>Immuno-stimulation leading to non-development of symptoms of CoVID-19 in risk population exposed to infected individuals. (Bala will be assessed by using specialised proforma including dashavidha pareeksha and other questionnaires which will reveal the physical and mental health of an individual.)Timepoint: Baseline, 15th day, 30th day, 45th day, 60th day and 90th day
Secondary Outcome Measures
NameTimeMethod
Improvement in quality of life( SF-36 per forma will be used)Timepoint: 12 week
© Copyright 2025. All Rights Reserved by MedPath